CAR-T Congress USA | Kisaco Research
A Collaborative Approach to Maximise the Potential of CAR-T
Boston, USA
20-22 March, 2018
Download Agenda
The Audience
Register

The Agenda

CAR-T USA Agenda

Take a look at the CAR-T Congress USA 2018 agenda

Why Attend

The CAR-T Congress gathers thought leaders from biotech, big pharma, academia and investment to address the challenges and opportunities of CAR-T therapies in both liquid and solid tumors.  Discussing the potential of CARs in alternative cell types, mechanisms behind toxicity and tumor targeting, this event will provide an in depth view into this expansive area.

Exploring ground-breaking developments into CAR-T therapy, the event will provide the opportunity to collaborate to create a commercially viable, effective and safe therapy.  

Key session topics include:

  • Alternative cell constructs: TCRs, gamma delta T cells, CAR-NK & CAR-Tregs
  • Commercialisation, regulation & implementation
  • Safety, control & the underlying mechanisms of toxicity
  • Scalability, automation & process development
  • Target identification & neoantigen discovery
  • Patient access & strategic considerations
  • Investment & partnering workshops


Introducing dedicated partnering & networking sessions, with high level workshops to navigate the investment landscape & meet emerging companies. Join us for a rare opportunity to hear first-hand from those shaping the industry.

Innovation Showcase

Submit innovation showcase application

100+
Attendees
15+
Hours of Dedicated Networking Time
50:50
ratio of Academia to Industry
25+
Speakers
15+
1-to-1 Meetings Available per Attendee

The Speakers

 

Ronald Dudek

Living Pharma

Ronald Dudek

Living Pharma
 

Laurence Cooper

Chief Executive Officer
Ziopharm

Laurence Cooper

Chief Executive Officer
Ziopharm
 

Joern-Peter Halle

Senior Vice President, Head Translational Innovation Platform Immuno-Oncology and Head External Innovation
Merck KGaA

Peter is leading the Translational Innovation Platform Immuno-Oncology with global responsibility for the research, discovery, and translational aspects of Merck KGaA’s IO portfolio. As the global head for External Innovation he oversees the search & evaluation of external opportunities in all therapeutic areas ranging from academic collaborations to clinical assets. He is also responsible for innovation initiatives of the healthcare business and a member of the investment committee of Merck Venture, Merck KGaA’s corporate VC.

Joern-Peter Halle

Senior Vice President, Head Translational Innovation Platform Immuno-Oncology and Head External Innovation
Merck KGaA

Peter is leading the Translational Innovation Platform Immuno-Oncology with global responsibility for the research, discovery, and translational aspects of Merck KGaA’s IO portfolio. As the global head for External Innovation he oversees the search & evaluation of external opportunities in all therapeutic areas ranging from academic collaborations to clinical assets. He is also responsible for innovation initiatives of the healthcare business and a member of the investment committee of Merck Venture, Merck KGaA’s corporate VC.

 

Neil Sheppard

Head External Co-operations & Early Development Leader
GSK

Neil Sheppard

Head External Co-operations & Early Development Leader
GSK
 

Robert Hofmeister

Chief Scientific Officer
TCR2

Robert Hofmeister

Chief Scientific Officer
TCR2
 

Matthew Hewitt

Principal Scientist/Director - Tumor Microenvironment
Bellicum Pharmaceuticals

Matthew Hewitt

Principal Scientist/Director - Tumor Microenvironment
Bellicum Pharmaceuticals
 

Dr Bijal Shah

MD Medical Oncology
Moffitt Cancer Center

Dr Bijal Shah

MD Medical Oncology
Moffitt Cancer Center
 

James Noble

CEO
Adaptimmune

James Noble

CEO
Adaptimmune
 

Bob Valamehr, PhD MBA,

Vice President, Cancer Immunotherapy
Fate Therapeutics Inc

Bob Valamehr, PhD MBA,

Vice President, Cancer Immunotherapy
Fate Therapeutics Inc
 

Andrew Allen

President & CEO,
Gritstone Oncology

Andrew Allen

President & CEO,
Gritstone Oncology
 

Dr David Sourdive, PhD

Executive Vice President Technical Operations
Cellectis

David Sourdive, Ph.D., is a co-founder of Cellectis and joined the Board of Directors in 2000. Dr. Sourdive holds the position of Executive Vice President, Technical Operations, with the mission to develop the Company’s industrial and technological basis as well as to deploy its operations in the pharmaceutical arena. Dr. Sourdive combines a strong scientific expertise with experience in managing industrial programs bringing innovative technologies to industrial fruition. He served as Executive Vice President, Corporate Development, from 2008 to 2016.

Dr David Sourdive, PhD

Executive Vice President Technical Operations
Cellectis

David Sourdive, Ph.D., is a co-founder of Cellectis and joined the Board of Directors in 2000. Dr. Sourdive holds the position of Executive Vice President, Technical Operations, with the mission to develop the Company’s industrial and technological basis as well as to deploy its operations in the pharmaceutical arena. Dr. Sourdive combines a strong scientific expertise with experience in managing industrial programs bringing innovative technologies to industrial fruition. He served as Executive Vice President, Corporate Development, from 2008 to 2016.

 

Dr Yangbing Zhao

Director of the T Cell Engineering Laboratory (TCEL)
Center for Cellular Immunotherapies at the University of Pennsylvania.

Dr. Yangbing Zhao is the Director of the T Cell Engineering Laboratory (TCEL), Center for Cellular Immunotherapies at the University of Pennsylvania. He received an MD and PhD in Immunology from the Third Medical University in Chongqing, China. From 1996 – 2000, he was a visiting scientist at The Weizmann Institute of Science in Rehovot, Israel, where he studied tolerance induction through genetically engineered T cells for allogeneic bone marrow transplantation.

Dr Yangbing Zhao

Director of the T Cell Engineering Laboratory (TCEL)
Center for Cellular Immunotherapies at the University of Pennsylvania.

Dr. Yangbing Zhao is the Director of the T Cell Engineering Laboratory (TCEL), Center for Cellular Immunotherapies at the University of Pennsylvania. He received an MD and PhD in Immunology from the Third Medical University in Chongqing, China. From 1996 – 2000, he was a visiting scientist at The Weizmann Institute of Science in Rehovot, Israel, where he studied tolerance induction through genetically engineered T cells for allogeneic bone marrow transplantation.

 

David Epstein

Chairman
Rubius Therapeutics & Executive Partner Flagship Pioneering

David Epstein

Chairman
Rubius Therapeutics & Executive Partner Flagship Pioneering
 

Gary C. Du Moulin, PhD

Adjunct Associate Professor of Regulatory Affairs
College of Pharmacy and Health Sciences University

Gary C. Du Moulin, PhD

Adjunct Associate Professor of Regulatory Affairs
College of Pharmacy and Health Sciences University
 

Lawrence Lamb

Co-Founder
Incysus

Lawrence Lamb

Co-Founder
Incysus
 

Michael Klichinsky

Co-Founder
CARMA Therapeutics

Michael Klichinsky

Co-Founder
CARMA Therapeutics
 

Stephane Boissel

CEO
TxCell

Stephane Boissel

CEO
TxCell
 

Russell Cruz

Assistant Professor
Children’s National Medical Center

Russell Cruz

Assistant Professor
Children’s National Medical Center

Media partners

Become a Sponsor or Exhibitor

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event
with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.
With our extensive marketing experience and strategy, your partnership with the conference will grant you a sponsorship package that is
an extension and enhancement of your current marketing and branding efforts.
CONTACT US: Ask us about the different ways you can get involved. Contact our sponsorship team to find out more about each package by
emailing [email protected] or by calling: +44 (0)20 3696 2925.

CAR-T Congress USA

March 20 - 22, 2018

Boston | MA

Visit www.car-tcongress.com

Venue

Hilton Boston Dedham Hotel, 25 Allied Drive, Dedham, MA, 0206

Hilton_Boston

Overlooking tranquil woods, and only 10 miles from downtown Boston, this year we've chosen the newly-renovated Hilton Boston/Dedham as our venue of choice.

Located off I-95, it is within close proximity to multiple train stations and there is a complimentary shuttle service allowing you to travel around easily.

Inside the hotel you’ll find modern and welcoming rooms and suites, great recreational amenities, vibrant local cuisine and stunning indoor/outdoor spaces. Book a room for only $109.00 + tax (based on single occupancy).

Book now

T: +1-781-329-7900

Remember to always quote “KISACO RESEARCH LTD” when booking.

Conference Packages

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: discounts cannot be combined.

Wednesday, November 1, 2017 to Sunday, April 1, 2018
Academic & Not-for-Profit | 2 Day Conference
$799
2 day conference pass
Refreshments, breakfast & lunch
Networking opportunities
Add commercialization day for $200
Friday, January 12, 2018 to Friday, February 9, 2018
Biopharma & Biotech | 2 Day Conference
$1,499
Early Bird until February 9 2018, standard rate $1,699
2 day conference pass
Refreshments, breakfast & lunch
Networking opportunities
Add commercialization day for $699
Friday, January 12, 2018 to Friday, February 9, 2018
Service Provider | 2 Day Conference
$1,699
Early Bird until 9 February 2018, standard rate $1,899
2 day conference pass
Refreshments, breakfast & lunch
Networking opportunities
Add commercialization day for $699
Friday, January 12, 2018 to Friday, February 9, 2018
Commercialization Day Only
$1,199
Early Bird until February 9 2018, standard rate $1,399
1 day commercialization pass
Refreshments, breakfast & lunch
Networking opportunities
Preparing registration...

Resources

Download Resource

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us